IMMX on Nasdaq

Immix Biopharma, Inc.

American pharmaceutical preparations company based in Los Angeles. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

TickerIMMX on Nasdaq¹
IndustryPharmaceutical Preparations¹
HeadquartersLos Angeles, California¹
Incorporated inDE²
Business address11400 West Olympic Blvd., Suite 200, Los Angeles, Ca 90064²
Filer category, Emerging growth company²
Legal formCorporation

See how the biggest companies compare on our leaderboards

Update- NEXICART-2” above for information regarding trial results as of November 13, 2025.³ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income⁴⁵⁶⁷⁸-$30.0M in 2025+6500% since 2020

Net income⁴⁶⁷⁸⁹-$29.4M in 2025+2461% since 2020

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31
General and administrative expenses	$13.7M	$11.4M
Research and development	$16.3M	$11.3M
Total operating expenses	$30.0M	$22.7M
Loss from operations	-$30.0M	-$22.7M
Interest income	$555.5K	$1.0M
Total other income	$555.5K	$1.0M
Loss before provision for income taxes	-$29.4M	-$21.7M
Provision for income taxes	$37.7K	$41.0K
Net loss	-$29.4M	-$21.7M
Net loss attributable to non-controlling interests		$85.0K
Net loss attributable to Immix Biopharma, Inc. common stockholders	-$29.4M	-$21.6M
Foreign currency translation	$61.2K	-$135.7K
Total other comprehensive income (loss)	$61.2K	-$135.7K
Comprehensive loss	-$29.4M	-$21.7M
Loss per common share - basic	-$0.89	-$0.76
Loss per common share - diluted	-$0.89	-$0.76
Weighted average shares outstanding - basic	33.0M shares	28.3M shares
Weighted average shares outstanding - diluted	33.0M shares	28.3M shares

Total assets⁴⁵⁶⁷⁸$104.8M in 2025+19329% since 2020

Total liabilities⁴⁵⁶⁷⁸$11.0M in 2025+110% since 2020

Shareholders’ equity⁴⁶⁷⁸$93.8M in 2025

Cash⁴⁵⁶⁷⁸$93.9M in 2025+23917% since 2020

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.⁸

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$93.9M	$17.7M
Short-term investments	$6.5M
Tax receivable		$2.0M
Prepaid expenses and other current assets	$828.3K	$541.5K
Total current assets	$101.2M	$20.2M
Other assets	$20.4K	$20.4K
Deferred offering costs	$93.6K
Right-of-use asset, net	$966.9K	$989.5K
Property and equipment, net	$2.5M	$1.7M
Total assets	$104.8M	$22.9M
Accounts payable and accrued expenses	$10.0M	$8.6M
Operating lease liabilities - current	$139.3K	$65.2K
Total current liabilities	$10.1M	$8.7M
Operating lease liabilities - long term	$933.6K	$1.0M
Total liabilities	$11.0M	$9.7M
Common stock, $0.0001 par value; 200,000,000 shares authorized; 53,023,466 shares issued and 52,951,103 shares outstanding at December 31, 2025, and 27,612,383 shares issued and 27,540,020 shares outstanding at December 31, 2024	$5.3K	$2.8K
Additional paid-in capital	$198.3M	$88.4M
Accumulated other comprehensive income	$60.2K	-$1.1K
Accumulated deficit	-$104.5M	-$75.0M
Treasury stock at cost, 72,363 shares as of December 31, 2025, and 2024	-$100.0K	-$100.0K
Total stockholders equity	$93.8M	$13.3M	$16.2M
Total liabilities and stockholders equity	$104.8M	$22.9M
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10.0M shares	10.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	200.0M shares	200.0M shares
Common stock, shares issued	53.0M shares	27.6M shares
Common stock, shares outstanding	53.0M shares	27.5M shares
Treasury stock, shares	72.4K shares	72.4K shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$93.9M	$17.7M
Short-term investments	$6.5M
Tax receivable		$2.0M
Prepaid expenses and other current assets	$828.3K	$541.5K
Total current assets	$101.2M	$20.2M
Other assets	$20.4K	$20.4K
Deferred offering costs	$93.6K
Right-of-use asset, net	$966.9K	$989.5K
Property and equipment, net	$2.5M	$1.7M
Total assets	$104.8M	$22.9M
Accounts payable and accrued expenses	$10.0M	$8.6M
Operating lease liabilities - current	$139.3K	$65.2K
Total current liabilities	$10.1M	$8.7M
Operating lease liabilities - long term	$933.6K	$1.0M
Total liabilities	$11.0M	$9.7M
Common stock, $0.0001 par value; 200,000,000 shares authorized; 53,023,466 shares issued and 52,951,103 shares outstanding at December 31, 2025, and 27,612,383 shares issued and 27,540,020 shares outstanding at December 31, 2024	$5.3K	$2.8K
Additional paid-in capital	$198.3M	$88.4M
Accumulated other comprehensive income	$60.2K	-$1.1K
Accumulated deficit	-$104.5M	-$75.0M
Treasury stock at cost, 72,363 shares as of December 31, 2025, and 2024	-$100.0K	-$100.0K
Total stockholders equity	$93.8M	$13.3M	$16.2M
Total liabilities and stockholders equity	$104.8M	$22.9M
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10.0M shares	10.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	200.0M shares	200.0M shares
Common stock, shares issued	53.0M shares	27.6M shares
Common stock, shares outstanding	53.0M shares	27.5M shares
Treasury stock, shares	72.4K shares	72.4K shares

Cash from operations⁴⁵⁶⁷⁸-$23.9M in 2025+5813% since 2020

Capital spending⁵⁷⁸$732.9K in 2025+91287% since 2021

Free cash flow⁵⁷⁸-$24.7M in 2025+1451% since 2021

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31
Net loss	-$29.4M	-$21.7M
Stock-based compensation	$2.4M	$3.0M
Depreciation	$245.7K	$32.9K
Amortization of right of use asset	$118.8K	$82.4K
Tax receivable	$2.1M	-$971.5K
Prepaid expenses and other current assets	-$286.7K	$554.8K
Other assets		-$20.4K
Accounts payable and accrued expenses	$1.0M	$4.4M
Operating lease liability	-$98.0K	$2.9K
Net cash used in operating activities	-$23.9M	-$14.6M
Purchase of property and equipment	-$732.9K	-$1.2M
Purchase of short-term investments	-$6.5M
Net cash used in investing activities	-$7.2M	-$1.2M
Payments of deferred offering costs	-$137.0K
Proceeds from exercise of stock options	$6.3K	$2.5K
Proceeds from exercise of stock warrants	$124.8K
Proceeds from sale of common stock, net of offering costs	$107.4M	$15.9M
Net cash provided by financing activities	$107.4M	$15.9M
Effect of foreign currency on cash	$3.8K	-$3.6K
Net change in cash and cash equivalents	$76.2M	$172.2K
Establishment of right of use asset and liabilities	$96.2K	$1.1M
Purchases of property and equipment included in accounts payable and accrued liabilities	$294.3K	$545.2K
Deferred offering costs charged against proceeds from sale of common stock	$43.4K	$87.2K
Shares issues in subsidiary absorption		$99
Shares issued for vested RSUs	$26

Compare Immix Biopharma, Inc. with another company

Leadership

Who has led Immix Biopharma, Inc., and when. Pick a name to see everywhere that person has worked.

2025

Chief executive officerIlya M. Rachman Dec 15, 2021 to now¹¹
ChairIlya M. Rachman Dec 15, 2021 to now¹¹
PresidentGabriel S. Morris May 29, 2026 to now¹²
Chief financial officerGabriel S. Morris Dec 15, 2021 to now¹³

Board members and other officers (10)

CMO & Head of Clinical Dev.Graham Ross Dec 15, 2021 to Dec 15, 2021¹⁴
Scientific Co-FounderVladimir P. Torchilin Dec 15, 2021 to Dec 20, 2021¹⁵
Board memberNancy T. Chang Sep 17, 2025 to now¹⁶
Board memberYekaterina Chudnovsky Aug 23, 2023 to now¹⁷
Board memberCarey Ng Dec 15, 2021 to now¹⁸
Board memberGabriel S. Morris Dec 15, 2021 to now¹³
Board memberHelen C. Adams Dec 15, 2021 to now¹⁹
Board memberJason Hsu Dec 15, 2021 to now²⁰
Board memberMagda Marquet Dec 15, 2021 to now²¹
Board memberMelissa Jane Buchan Dec 15, 2021 to now²²

Named in SEC Form D filings

People the company listed in its private-offering notices.

DirectorJane Buchan named May 20, 2024²³

Timeline

Dec 15, 2021New chief executive Ilya M. Rachman becomes CEO¹¹

Filings

237 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 34 major events, 96 insider forms, 15 large holders, 1 private raises, 69 other. The latest 20:

Sep 30, 20268-K EDGAR
Sep 29, 2026FWP EDGAR
Sep 29, 2026424B5 EDGAR
Sep 29, 20268-K EDGAR
Aug 14, 2026SCHEDULE 13G EDGAR
Aug 13, 2026SCHEDULE 13G/A EDGAR
Aug 7, 202610-Q EDGAR
Jul 20, 20268-K EDGAR
Jun 5, 2026SCHEDULE 13G/A EDGAR
May 29, 20268-K EDGAR
May 29, 20264 EDGAR
May 29, 20264 EDGAR
May 29, 20264 EDGAR
May 29, 20264 EDGAR
May 29, 20264 EDGAR
May 29, 20264 EDGAR
May 29, 20264 EDGAR
May 29, 20264 EDGAR
May 29, 20264 EDGAR
May 21, 20268-K EDGAR

The 237 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

42 open-market trades by officers, directors and large owners since October 2021: 40 buys and 2 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Dec 10, 2025	Rachman Ilya MCEO and Chairman	Buy	746	$6.67	$5.0K	Form 4
Dec 10, 2025	Morris Gabriel SCFO, President	Buy	770	$6.58	$5.1K	Form 4
Sep 17, 2025	Rachman Ilya MCEO and Chairman	Buy	2,500	$2.02	$5.0K	Form 4
Sep 16, 2025	Morris Gabriel SCFO, President	Buy	2,600	$1.97	$5.1K	Form 4
Jun 18, 2025	Rachman Ilya MCEO and Chairman	Buy	2,178	$2.30	$5.0K	Form 4
Jun 18, 2025	Morris Gabriel SCFO, President	Buy	2,225	$2.28	$5.1K	Form 4
Dec 23, 2024	Hsu JasonDirector	Buy	40,000	$2.19	$87.6K	Form 4
Dec 20, 2024	Hsu JasonDirector	Buy	7,700	$2.17	$16.7K	Form 4
Aug 22, 2024	Hsu JasonDirector	Buy	8,100	$2.25	$18.2K	Form 4
Aug 21, 2024	Hsu JasonDirector	Buy	15,000	$2.23	$33.5K	Form 4
Aug 16, 2024	Ng CareyDirector	Buy	10,000	$1.86	$18.6K	Form 4
Jul 24, 2024	Hsu JasonDirector	Buy	6,000	$2.15	$12.9K	Form 4
Jul 18, 2024	Hsu JasonDirector	Buy	3,200	$2.07	$6.6K	Form 4
Jun 7, 2024	Morris Gabriel SCFO, President	Buy	2,500	$2.12	$5.3K	Form 4
Jun 7, 2024	Rachman Ilya MCEO and Chairman	Buy	2,600	$2.13	$5.5K	Form 4
Jun 4, 2024	Morris Gabriel SCFO, President	Buy	3,300	$1.81	$6.0K	Form 4
Jun 4, 2024	Rachman Ilya MCEO and Chairman	Buy	3,300	$1.81	$6.0K	Form 4
May 14, 2024	Morris Gabriel SCFO, President	Buy	4,500	$2.23	$10.0K	Form 4
May 14, 2024	Rachman Ilya MCEO and Chairman	Buy	4,300	$2.25	$9.7K	Form 4
Dec 11, 2023	Hsu JasonDirector	Buy	31,000	$4.67	$144.8K	Form 4

All 42 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

EVENTIDE ASSET MANAGEMENT, LLCSCHEDULE 13G, 1 filing Aug 14, 2026²⁴
Janus Henderson Group Ltd.SCHEDULE 13G/A, 4 filings Feb 17, 2026 to Aug 13, 2026²⁵
MILLENNIUM MANAGEMENT LLCSCHEDULE 13G/A, 2 filings Mar 20, 2026 to May 4, 2026²⁶
Saturn V Capital Management LPSCHEDULE 13G, 1 filing Feb 17, 2026²⁷
Orin HirschmanSCHEDULE 13G/A, 2 filings Feb 7, 2024 to Jan 29, 2025²⁸
GKCC, LLCSC 13D, 1 filing Aug 30, 2023²⁹
Murchinson Ltd.SC 13G/A, 2 filings Feb 9, 2022 to Mar 2, 2022³⁰
Altium Capital Management LLCSC 13G/A, 2 filings Dec 28, 2021 to Feb 11, 2022³¹

Money raised

Private offerings the company reported to the SEC on Form D.

May 20, 2024Filed a private offering of equity Form D: 14 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Jupiter Topco LLC	9,783,192	$100.8M	0.0%	New
Saturn V Capital Management LP	4,658,429	$48.0M	6.9%	+964,844
Eventide Asset Management, LLC	3,891,019	$40.1M	0.5%	+1,342,000
State Street Corp	2,996,935	$30.9M	0.0%	+2,805,025
BlackRock, Inc.	2,989,972	$30.8M	0.0%	+2,521,595
Deep Track Capital, LP	2,775,000	$28.6M	0.4%	New
Vanguard Capital Management LLC	2,507,122	$25.8M	0.0%	+719,128
Opaleye Management Inc.	2,345,000	$24.2M	2.2%	New
Millennium Management LLC	2,066,426	$21.3M	0.0%	+316,226
UBS Group AG	1,941,817	$20.0M	0.0%	+1,864,985
Marshall Wace, Llp	1,794,908	$18.5M	0.0%	+153,356
Wellington Management Group Llp	1,473,409	$15.2M	0.0%	New
Great Point Partners LLC	1,277,642	$13.2M	3.1%	+927,642
Geode Capital Management, LLC	1,201,097	$12.4M	0.0%	+737,713
Velan Capital Investment Management LP	1,085,000	$11.2M	6.9%	+345,000
Bleichroeder LP	1,000,000	$10.3M	1.8%	No change
Logos Global Management LP	1,000,000	$10.3M	0.4%	−225,000
Franklin Resources Inc	969,120	$10.0M	0.0%	+54
Burkehill Global Management, LP	544,118	$5.6M	0.2%	+250,000
Ameriprise Financial Inc	518,881	$5.3M	0.0%	New
Citadel Advisors LLC	506,157	$5.2M	0.0%	+458,984
Blue Owl Capital Holdings LP	437,552	$4.5M	0.7%	−110,000
Northern Trust Corp	418,051	$4.3M	0.0%	+279,819
Balyasny Asset Management L.P.	417,227	$4.3M	0.0%	New
LGT Fund Management Co Ltd.	416,594	$4.3M	0.2%	No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARImmix Biopharma, Inc. filings on SEC EDGAR
2
SEC EDGARImmix Biopharma, Inc. filings on SEC EDGAR
3
SEC EDGARImmix Biopharma, Inc. annual report, Item 1 (Business)
4
SEC EDGARImmix Biopharma, Inc. 10-K for fiscal 2020
5
SEC EDGARImmix Biopharma, Inc. 10-K for fiscal 2021
6
SEC EDGARImmix Biopharma, Inc. 10-K for fiscal 2022
7
SEC EDGARImmix Biopharma, Inc. 10-K for fiscal 2023
8
SEC EDGARImmix Biopharma, Inc. 10-K for fiscal 2024
9
SEC EDGARImmix Biopharma, Inc. 10-K for fiscal 2025
10
SEC EDGARImmix Biopharma, Inc. 10-Q for fiscal 2026
11
SEC EDGARIlya M. Rachman, Chief executive officer
12
SEC EDGARGabriel S. Morris, President
13
SEC EDGARGabriel S. Morris, Chief financial officer
14
SEC EDGARGraham Ross, CMO & Head of Clinical Dev.
15
SEC EDGARVladimir P. Torchilin, Scientific Co-Founder
16
SEC EDGARNancy T. Chang, Board member
17
SEC EDGARYekaterina Chudnovsky, Board member
18
SEC EDGARCarey Ng, Board member
19
SEC EDGARHelen C. Adams, Board member
20
SEC EDGARJason Hsu, Board member
21
SEC EDGARMagda Marquet, Board member
22
SEC EDGARMelissa Jane Buchan, Board member
23
SEC EDGARImmix Biopharma, Inc. Form D naming Jane Buchan
24
SEC EDGAREVENTIDE ASSET MANAGEMENT, LLC SCHEDULE 13G on Immix Biopharma, Inc.
25
SEC EDGARJanus Henderson Group Ltd. SCHEDULE 13G/A on Immix Biopharma, Inc.
26
SEC EDGARMILLENNIUM MANAGEMENT LLC SCHEDULE 13G/A on Immix Biopharma, Inc.
27
SEC EDGARSaturn V Capital Management LP SCHEDULE 13G on Immix Biopharma, Inc.
28
SEC EDGAROrin Hirschman SCHEDULE 13G/A on Immix Biopharma, Inc.
29
SEC EDGARGKCC, LLC SC 13D on Immix Biopharma, Inc.
30
SEC EDGARMurchinson Ltd. SC 13G/A on Immix Biopharma, Inc.
31
SEC EDGARAltium Capital Management LLC SC 13G/A on Immix Biopharma, Inc.